Skip to main content

zelenectide pevedotin

Generic: Zelenectide Pevedotin

zelenectide pevedotin: developed by 1 company · 2 clinical trials tracked.

zelenectide pevedotin evidence translation

What we can confirm

What it means

Source-backed records connect zelenectide pevedotin to BCYC; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could zelenectide pevedotin → BCYC affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 1 study sponsors

Related indications

metastatic urothelial cancerNectin-4 expressing tumors (oncology), including metastatic urothelial cancer; NECTIN4 gene-amplified triple-negative breast cancer and non-small cell lung cancerHigh Nectin-4 expressing tumors; treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer; Nectin-4 expressing advanced malignanciesAdvanced Solid TumorsNon-Small Cell Lung Cancer
Development Pipeline (3)
CompanyPhase
BICYCLE THERAPEUTICS PLC (BCYC)
metastatic urothelial cancer
Phase 2
BICYCLE THERAPEUTICS PLC (BCYC)
Nectin-4 expressing tumors (oncology), including metastatic …
Phase 2
BICYCLE THERAPEUTICS PLC (BCYC)
High Nectin-4 expressing tumors; treatment of adult patients…
Phase 2
Clinical Trials (2)

Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product on a BicycleTx Limited-Sponsored Study

NCT07681674·Phase 2
Not yet recruiting

Primary endpoint: Monitor safety for participants receiving a Bicycle investigational product

Interventionalopen16 targetStarted 2026-08Completion 2030-05BicycleTx Limited

Phase 2 Study of Zelenectide Pevedotin in Participants With Previously-Treated NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

NCT06933329·Phase 2·MRUS
Recruiting

Primary endpoint: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by Investigator

Interventionalopen73 targetStarted 2025-07Completion 2029-0225 sites · France, Spain, United Kingdom, United StatesBicycleTx Limited

Frequently asked questions

Who is developing zelenectide pevedotin?

zelenectide pevedotin is being developed by BICYCLE THERAPEUTICS PLC.

How many clinical trials involve zelenectide pevedotin?

BioSniper tracks 2 clinical trials involving zelenectide pevedotin.